The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver.

Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver.

A method for preparing the cyclic phosphonate compound of Formula I ##STR00001##
is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

The present application describes a thyroid hormone receptor ? subtype agonist derivative, a preparation method and a use thereof.

The present invention relates to a novel phenanthroline phosphonic acid compound and a pharmaceutical salt thereof, as well as an application of the compound and the pharmaceutical salt thereof as collagen prolyl hydroxylase inhibitors in the preparation of drugs for preventing or treating collagen prolyl-4-hydroxylase related disease.

The invention relates to novel and improved halogen-free flame retardant compounds having the structure of Formula (I): wherein: R.sup.1 and R.sup.2 are independently hydrogen, C.sub.1-C.sub.6 alkyl, P(O)(OR.sup.3).sub.2, P(O)OR.sup.3R.sup.4, or P(O)R.sup.3.sub.2, wherein R.sup.3 and R.sup.4 are independently C.sub.1-C.sub.4 alkyl, C.sub.6-C.sub.12 aryl, C.sub.7-C.sub.15 aralkyl or C.sub.7-C.sub.15 alkaryl; or R.sup.1 and R.sup.2 taken together form an unsaturated cyclic ring, which is optionally substituted by an alkyl group; each k is independently an integer from 1 to 2; each X is independently oxygen (O) or sulphur (S); v is 0 or 1; each Y is independently C.sub.1-C.sub.4 alkylene, C.sub.6 arylene, C.sub.7-C.sub.15 aralkylene, C.sub.7-C.sub.15 alkarylene, oxygen (O), nitrogen (NR), wherein R is H or C.sub.1-C.sub.4 alkyl; n is 0, 1 or 2 with the proviso that n is 1 when Y is oxygen (O) or nitrogen (NR); each Z is independently C.sub.1-C.sub.4 alkylene, C.sub.6 arylene, C.sub.7-C.sub.15 aralkylene or C.sub.7-C.sub.15 is alkarylene; m is independently 0, 1 or 2; with the proviso that when Y is oxygen (O) or nitrogen (N), m cannot be 0; each Q is independently C.sub.1-C.sub.4 alkylene; t is an integer from 1 to 2; W is oxygen (O) or sulphur (S). The compounds are particularly suited as flame retardant additives for thermoplastic polyesters.

Provided herein are a series of fluorescently labeled phosphonate and phosphate compounds such as can be used for affinity probes to detect certain enzymes including lipases. Also provided are methods of making and using such compounds.

The present relates to flame-retardant expandable polymers and to polymer foams and to the use thereof. These flame-retardant expandable polymers and polymer foams can be contained in one or several pressurized containers. According to the present, at least one of the following phosphorus compounds is used as a flame retardant: phosphorus compound according to formula (Ia): (Ia) 10-hydroxy-9, 10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide (DOPO-OH); or the salts thereof according to formula (Ib): (Ib) (DOPO-OR); or the ring-opened hydrolysates thereof according to formula (Ic): (Ic).